CUHK
News Centre

The Chinese University of Hong Kong (CUHK) has appointed Dr. Daniel HS Lee as Associate Vice-President (Innovation and Enterprise) for a period of three years from 27 May 2019.

Dr. Lee will assist the Pro-Vice-Chancellor (Strategic Developments) in spearheading the strategic management and commercial development of the University’s research enterprise. Dr. Lee will take the lead in advancing research excellence through fostering research performance and intensity, promoting knowledge exchange in the University community, engaging a wide range of stakeholders from students and researchers to industry and strengthening global links. He will at the same time formulate a comprehensive strategy, delivering directives in corporate policies, best practices and procedures that meet the highest standards of ethics, integrity and ensuring compliance with regulatory requirements, thereby accelerating CUHK’s research excellence and societal impact to the global community.

Dr. Lee is pleased to accept the appointment, “I am excited and honoured to have this opportunity of serving CUHK. I look forward to working with all the staff, students and alumni of CUHK, and all the stakeholders from academia, industry and organisations to government authorities, to drive innovation and entrepreneurship to a fruition that benefits the patients and the underserved and contributes to the success of CUHK and Hong Kong.”

Dr. Lee is a clinical biochemist and has been an Advisory Committee Member of the School of Pharmacy, and Scientific Advisor of the Clinical Trial Centre, Prince of Wales Hospital, for CUHK. He obtained his BSc and PhD in Pathology from The University of Hong Kong. After teaching at The University of Hong Kong for seven years, he joined the pharmaceutical industry and served for over 25 years in pharma companies including Johnson and Johnson USA, Biogen USA, GSK China and served as General Manager and Head of site for Roche Pharma R&D China from 2010. He has broad experience of both small molecule and biologic drug discovery and development, including companion diagnostics, covering therapeutic areas from central nervous system, infectious diseases, diabetes complications to oncology and inflammation. He joined the Hong Kong Science and Technology Parks Corporation as Head of the Biomedical Technology Cluster from 2013 to 2018 and contributed significantly to the biotech industry and translational medicine development in Hong Kong. He has published over 50 peer-reviewed papers, actively engaged in teaching and journal manuscript reviews, and co-invented 14 published patents. He has served as CEO and board director of biotech companies, consultant for several institutes and companies, Adjunct Professor of the Division of Life Science, The Hong Kong University of Science and Technology and Honorary Professor of the Faculty of Medicine, The University of Hong Kong.